Teva's Huntington's Pursuit Lends Insight Into Other Diseases
This article was originally published in Scrip
Executive Summary
Teva, mostly known for being the world's largest generic company and the maker of the multiple sclerosis drug Copaxone (glatiramer acetate injection), has ventured into the rare disease area, pursuing an orphan medicine for Huntington's disease, a fatal neurodegenerative condition that affects about 30,000 Americans.